Reviews/Parkinsons Disease Management/No proven disease-modifying therapy in Parkinson's
PD NEURO · PD-05 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The corpus contains one trial of a Parkinson's disease drug run at the largest, confirmatory stage of testing, exenatide [4], and it failed to slow the disease. Every other drug studied here was tested at an earlier stage, and most of those also failed to beat placebo on motor-disability scores [6][7][8][9]. One earlier-stage drug, lixisenatide [5], did show a genuine benefit, but it has not yet been tested at the confirmatory stage. The panel saw nothing in this corpus showing a confirmatory-stage trial that clearly protected the brain or slowed the disease. It treated the claim as well supported but noted it leans heavily on that single confirmatory trial.
The only Phase 3 disease-modification trial in the corpus, exenatide [4], was negative: MDS-UPDRS part III worsened similarly in both arms (adjusted coefficient 0.92, 95% CI -1.56 to 3.39; p=0.47). Every other candidate sits at Phase 1 or 2 — nicotinamide riboside [1], CNM-Au8 [2], lixisenatide [5], deferiprone [6], NLY01 [7], nilotinib [8] and UDCA [9]. Of these, deferiprone was worse than placebo (difference 9.3 points; p<0.001) [6] and NLY01 showed no difference (p=0.77; p=0.79) [7]. The sole positive clinical signal, lixisenatide [5], is explicitly a Phase 2 result (difference 3.08, 95% CI 0.86 to 5.30; p=0.007). No corpus paper reports a Phase 3 trial that demonstrated robust disease modification. The contested point: The division is coverage, not direction: the universal negative over all Phase 3 trials rests on a single Phase 3 data point [4] plus the absence of any positive one. Lixisenatide [5] is a statistically significant disease-modification signal, so the claim survives only because [5] is Phase 2 and does not breach the Phase-3 scope.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Parkinsons Disease Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus contains only ONE Phase 3 trial (exenatide [4]); a universal negative across all Phase 3 trials cannot be comprehensively established from a single Phase 3 data point plus absence of positive examples.
Lixisenatide [5] showed a statistically significant positive disease-modification signal (difference 3.08, 95% CI 0.86 to 5.30; p=0.007); the claim survives only on its explicit Phase-3 scoping, and a looser reading would be partially contradicted.
Where it remains uncertain. The only positive disease-modification signal, lixisenatide [5] (difference 3.08, 95% CI 0.86 to 5.30; p=0.007), is explicitly Phase 2, so it informs but does not contradict a Phase-3-scoped claim.
Aleatory
Individual trials are modest (N=194 [4], N=156 [5], N=30 [9]), so chance variation in motor scores limits how firmly any single result settles the question.
Epistemic
Only exenatide [4] reached Phase 3 in the corpus; the broader Phase 3 landscape is unobserved here, so a universal Phase-3 negative is inferred from a single trial plus absence.
Inferential
The claim does not fix a threshold for 'robust' disease modification, so classifying any given result requires a judgement the corpus does not supply.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
The single Phase 3 DMT trial in the corpus returned a negative primary endpoint, directly supporting the claim.
“adjusted coefficient for the effect of exenatide 0·92 [95% CI -1·56 to 3·39]; p=0·47”
Panel auditInternal validity: high · scope of inference: Whether exenatide slows motor progression in people with established PD on dopaminergic treatment at Hoehn and Yahr ≤2.5.Key limitations: authors flag possible inadequate target engagement · moderate sample (n=194) · single agent
The corpus's only positive disease-modification signal is a Phase 2 trial, not Phase 3, so it does not contradict the claim.
“Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease.”
Panel auditInternal validity: medium · scope of inference: Effect of lixisenatide on motor-disability progression in early PD without motor complications over 12 months.Key limitations: phase 2, not phase 3 · modest effect and short follow-up · washout difference small (17.7 vs 20.6) · authors call for longer, larger trials
A Phase 2 DMT candidate failed, reinforcing absence of robust neuroprotection.
“deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks.”
Panel auditInternal validity: high · scope of inference: Effect of deferiprone on disease progression in newly diagnosed, levodopa-naive early PD over 36 weeks.Key limitations: phase 2, not phase 3 · differential dopaminergic rescue (22.0% vs 2.7%) · agranulocytosis/neutropenia safety signal · 36-week duration
The abstract reports biochemical and metabolic changes and only an uncontrolled 'mild clinical improvement' in a subgroup, with no between-group disease-progression outcome to judge disease modification.
Panel auditInternal validity: low · scope of inference: Short-term safety, cerebral NAD augmentation and metabolic effects of nicotinamide riboside in newly diagnosed PD.Key limitations: phase I, n=30 · 30-day duration · no disease-progression endpoint · clinical improvement uncontrolled and subgroup-only
4 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The claim is strongly consistent with the corpus, but its universality over 'Phase 3 trials' rests on a single Phase 3 data point, warranting Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Confirmatory Phase 3 for a positive candidate. The only positive disease-modification signal, lixisenatide [5], is Phase 2; the corpus holds no Phase 3 test of it. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large, long-duration Phase 3 RCT of lixisenatide with an off-medication MDS-UPDRS III disease-progression primary endpoint.
Open question: Would lixisenatide's Phase 2 disease-modification benefit replicate in a confirmatory Phase 3 trial? Why it is still open: The positive signal in [5] (difference 3.08, 95% CI 0.86 to 5.30; p=0.007) is explicitly Phase 2 and the authors call for longer and larger trials.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19